February 4th, 2019 sees the launch of the Longevity Leaders Conference in St Paul’s, London, which promises to be an interesting event on the conference calendar.
The conference aims to cover both the science of aging research and the business side of the industry, in a similar manner to our own annual conference, Ending Age-Related Diseases, which we host in New York. Mixing the worlds of science and business is a good idea as we move ever closer to the first true rejuvenation technologies arriving.
It is essential to begin forging bonds between the researchers who are making the science a reality and the investors and angels who have the knowledge and expertise to take the science to market.
Such events are, therefore, an excellent opportunity to make connections with others in the industry and to learn the best practices when it comes to developing therapies and preparing them for the challenging journey through regulatory systems and finally to market.
This conference will see thought leaders from research, technology, financial services, government, and the investment community coming together to discuss the future challenges and opportunities that we could face in a new age of medicine and in a world where aging and how we treat it may change dramatically.
There are many important speakers attending the event, including:
Dr. Alex Zhavoronkov, the CEO of Insilico Medicine, a Baltimore-based leader in next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research.
Alex is well known for his innovative work with AI, particularly the application of deep learning in cancer, pharmaceutical, and aging research. He serves on the editorial boards of high-impact journals such as Aging, Aging Research Reviews, Frontiers in Genetics of Aging, and he chairs the Annual Aging Research for Drug Discovery Forum (5th annual in 2018) and the Artificial Intelligence for Healthcare Forum (2nd annual) at Basel Life, one of Europe’s largest industry events in drug discovery.
Alex will be part of the 9:20 AM keynote panel discussion, The Future of the Science of Aging, along with Mike West from Agex and Aubrey de Grey from the SENS Research Foundation.
No conference about aging research would be complete without Dr. Aubrey de Grey, and this one is no exception. Aubrey is rightfully considered one of the original founders of the field and has been a devoted advocate of rejuvenation biotechnology for over a decade.
Aubrey is the Chief Science Officer at the SENS Research Foundation, a non-profit based in Mountain View, California, which takes a repair-based approach to aging and age-related disease. Quite simply, SENS proposes that the damage that aging causes can be periodically repaired in much the same way that one might service a car in order to keep it running.
The concept of damage repair was originally viewed with skepticism, but as more and more data has arrived in support of the proposal, this engineering approach to aging has gained traction. In fact, right now, the first true rejuvenation therapy based on this idea is now in human trials.
Dr. James Peyer is the founder and Managing Partner of Apollo Ventures, an early-stage life science investor and company builder that focuses on breakthrough technologies for treating age-related diseases.
James is a particularly intriguing figure in the industry, as he has a foot in both early-stage research and investment, so he has a fairly unique perspective to share. We certainly enjoyed the talk that he gave at our conference earlier this year, and given his varied background and experience, we feel certain that James should provide some valuable insights.
James will be delivering the 10 AM investor keynote, Navigating the Valley of Death and Reaping the Longevity Dividend.
The funding crisis in basic science
We are also pleased to confirm that the LEAF team will be at the event, and we will be curating a special discussion panel at 16:15, The Funding Crisis in Basic Science, where we will be taking a look at the biggest bottleneck to progress, which is the lack of funding for initial, basic research, which is the foundation for developing therapies and taking them to market.
LEAF board director Steve Hill will be moderating the discussion panel with a number of guests, and we hope that it will prove to be a thought-provoking discussion about this serious issue. We would like to thank LSX for organizing the conference and giving us the opportunity to address this important topic.
Steve and other team members will also be around all day at the conference if you would like to have a chat or ask us more about our work; we would love to meet you!
The conference will be held at etc.venues 200 Aldersgate, London, which offers an interesting and well-featured place to hold such an important event. The event opens February 4th at 8:00 AM with a coffee and networking session followed by the opening ceremony at 9:00 AM. To learn more and book tickets, visit the LSX website.